Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Tyrosine Kinase

Tyrosine Kinase

Products for  Tyrosine Kinase

  1. Cat.No. Product Name Information
  2. GC44977 Syk Inhibitor

    OXSI 2, Spleen Tyrosine Kinase

     Syk Inhibitor is a bioavailable, cell-permeable Syk inhibitor with an EC50 of 313 nM and an IC50 of 14 nM. Syk Inhibitor Chemical Structure
  3. GC44978 Syk Inhibitor II

    Spleen Tyrosine Kinase Inhibitor II

     Spleen tyrosine kinase (Syk) is a non-receptor tyrosine kinase that upon phosphorylation binds to immunoreceptor tyrosine-based activation motifs and mediates downstream signaling. Syk Inhibitor II Chemical Structure
  4. GC61942 Syk-IN-1 Syk-IN-1 (compound 4) is a potent Syk inhibitor, with an IC50 of 35 nM. Syk-IN-1 Chemical Structure
  5. GC62592 Syk-IN-4 Syk-IN-4 is a potent, selective and orally bioavailable SYK inhibitor with an IC50 of 0.31 nM. Syk-IN-4 Chemical Structure
  6. GC62268 SYN1143 SYN1143 is a potent, selective and orally active dual inhibitor of c-Met/RON, with IC50s of 4 and 9 nM, respectively. SYN1143 has weak inhibitory activity on Lck, Tie2, Src, and BTK with IC50s ranging from 160 to 710 nM. SYN1143 can be used for the research of cancers that RON and c-Met are activated. SYN1143 Chemical Structure
  7. GC65395 T025

    T025 is an orally active and highly potent inhibitor of Cdc2-like kinase (CLKs), with Kd values of 4.8, 0.096, 6.5, 0.61, 0.074, 1.5 and 32 nM for CLK1, CLK2, CLK3, CLK4, DYRK1A, DYRK1B and DYRK2, respectively. 

     T025 Chemical Structure
  8. GC33168 T338C Src-IN-1 T338C Src-IN-1 is a potent mutant-Src T338C inhibitor; exhibited the most potent inhibition of T338C(IC50=111 nM) relative to WT c-Src (10-fold increase). T338C Src-IN-1 Chemical Structure
  9. GC33181 T338C Src-IN-2

    T338C Src-IN-2 is a potent mutant c-Src T338C kinase inhibitor with IC50 of 317 nM; also inhibits T338C/V323A and T338C/V323S with IC50 of 57 nM/19 nM.

     T338C Src-IN-2 Chemical Structure
  10. GC16821 TAE226(NVP-TAE226)

    TAE 226;TAE-226

     TAE226(NVP-TAE226) (TAE226) is a potent and ATP-competitive dual FAK and IGF-1R inhibitor with IC50s of 5.5 nM and 140 nM, respectively. TAE226(NVP-TAE226) Chemical Structure
  11. GC16694 TAE684 (NVP-TAE684)

    TAE 684

     A selective ALK inhibitor TAE684 (NVP-TAE684) Chemical Structure
  12. GC11172 TAK-285 HER2/EGFR(HER1) inhibitor TAK-285 Chemical Structure
  13. GC10220 TAK-593 dual VEGFR/PDGFR inhibitor TAK-593 Chemical Structure
  14. GC37723 TAK-659 TAK-659 is a highly potent, selective, reversible and orally available dual inhibitor of spleen tyrosine kinase (SYK) and fms related tyrosine kinase 3 (FLT3), with an IC50 of 3.2 nM and 4.6 nM for SYK and FLT3, respectively. TAK-659 induces cell death in tumor cells but not in nontumor cells, and with potential for the treatment of chronic lymphocytic leukemia (CLL). TAK-659 Chemical Structure
  15. GC19344 TAK-659 hydrochloride TAK-659 hydrochloride is a potent, selective and orally available spleen tyrosine kinase (Syk) inhibitor with an IC50 of 3.2 nM. TAK-659 hydrochloride Chemical Structure
  16. GC49700 Takeda-6d Takeda-6d Chemical Structure
  17. GC62351 Taletrectinib

    DS-6051b; AB-106

     Taletrectinib (DS-6051b) is a potent, orally active, and next-generation selective ROS1/NTRK inhibitor. Taletrectinib potently inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3 with IC50s of 0.207, 0.622, 2.28, and 0.98 nM, respectively. Taletrectinib also inhibits ROS1 G2032R and other Crizotinib-resistant ROS1 mutants. Taletrectinib Chemical Structure
  18. GC37733 TAM-IN-2 TAM-IN-2 is a TAM inhibitor extracted from patent US 20170275290 A1, pyrrolotriazine compound 0904. TAM-IN-2 Chemical Structure
  19. GC15254 Tandutinib (MLN518)

    CT 53518, MLN518

     Tandutinib (MLN518) (MLN518) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib (MLN518) can be used for acute myelogenous leukemia (AML). Tandutinib (MLN518) has the ability to cross the blood-brain barrier. Tandutinib (MLN518) Chemical Structure
  20. GC12251 Tandutinib (MLN518) HCl FLT3 inhibitor,potent and selective Tandutinib (MLN518) HCl Chemical Structure
  21. GC38853 Tandutinib hydrochloride

    MLN518 hydrochloride; CT53518 hydrochloride

     Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML). Tandutinib hydrochloride has the ability to cross the blood-brain barrier. Tandutinib hydrochloride Chemical Structure
  22. GN10737 Tanshinone IIA

    NSC 686518, NSC 686519, TSA

     Tanshinone IIA Chemical Structure
  23. GC69990 Tarcocimab

    OG1953

    Tarcocimab (OG1953) is a humanized monoclonal antibody (IgG1 type) against VEGFA. Tarcocimab can be used for research on retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD).

     Tarcocimab Chemical Structure
  24. GC32100 Tarloxotinib bromide (TH-4000)

    TH-4000

    Tarloxotinib bromide is an irreversible EGFR/HER2 inhibitor.

     Tarloxotinib bromide (TH-4000) Chemical Structure
  25. GC33173 TAS-115

    TAS-115

     TAS-115 (TAS-115) is a potent VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively. TAS-115 Chemical Structure
  26. GC33273 TAS-115 mesylate (TAS-115 methanesulfonate)

    TAS-115 mesylate

     Pamufetinib (TAS-115) mesylate is a potent VEGFRand hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor, with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively. TAS-115 mesylate (TAS-115 methanesulfonate) Chemical Structure
  27. GC19156 TAS-120

    TAS-120

     TAS-120 (TAS-120) is an orally bioavailable, highly selective, and irreversible FGFR inhibitor, with IC50s of 3.9, 1.3, 1.6, and 8.3 nM for FGFR 1-4, respectively. TAS-120 inhibits mutant and wild-type FGFR2 with similar IC50s (wild-type FGFR2=0.9nM; V5651=1-3nM; N550H=3.6nM; E566G=2.4nM). TAS-120 Chemical Structure
  28. GC65310 TAS0728 TAS0728 is a potent, selective, orally active, irreversible and covalent-binding HER2 inhibitor, with an IC50 of 13 nM. TAS0728 also shows IC50s of 4.9, 8.5, 31, 65, 33, 25 and 86 nM for BMX、HER4、BLK、EGFR、JAK3、SLK and LOK respectively. Furthermore, TAS0728 exhibits robust and sustained inhibition of the phosphorylation of HER2 TAS0728 Chemical Structure
  29. GC32752 TAS6417

    TAS6417; CLN-081

     TAS6417 (CLN-081) is a highly effective, orally active and pan-mutation-selective EGFR tyrosine kinase inhibitor with a unique scaffold fitting into the ATP-binding site of the EGFR hinge region, with IC50 values ranging from 1.1-8.0 nM. TAS6417 Chemical Structure
  30. GC31676 Tavilermide (MIM-D3)

    MIM-D3

     Tavilermide (MIM-D3) is a selective, partial agonist of TrkA, or a nerve growth factor (NGF) mimetic. Tavilermide (MIM-D3) Chemical Structure
  31. GC37746 tBID tBID is a selective inhibitor of homeodomain-interacting protein kinase 2 (HIPK2) with an IC50 of ?0.33 ?M. tBID Chemical Structure
  32. GC12058 TCS 359

    Fms-like Tyrosine Kinase Inhibitor, TCS 359

     Potent FLT3 inhibitor TCS 359 Chemical Structure
  33. GC11763 Telatinib (BAY 57-9352)

    BAY 579352;BAY 57 9352

     Telatinib (BAY 57-9352) (Bay 57-9352) is an orally active, small molecule inhibitor of VEGFR2, VEGFR3, PDGFα, and c-Kit with IC50s of 6, 4, 15 and 1 nM, respectively. Telatinib (BAY 57-9352) Chemical Structure
  34. GC63214 Telatinib mesylate

    Bay 57-9352 mesylate

     Telatinib mesylate (Bay 57-9352 mesylate) is a potent and orally active VEGFR2, VEGFR3, PDGFα, and c-Kit inhibitor with IC50s of 6 nM, 4 nM, 15 nM and 1 nM, respectively. Telatinib mesylate Chemical Structure
  35. GC41577 Tephrosin (synthetic)

    Deguelinol I, Hydroxydeguelin

     Tephrosin (synthetic) is a natural rotenoid which has potent antitumor activities. Tephrosin (synthetic) induces degradation of of EGFR and ErbB2 by inducing internalization of the receptors. Tephrosin (synthetic) Chemical Structure
  36. GC70013 Teprotumumab

    Teprotumumab is a human monoclonal antibody that blocks the insulin-like growth factor-1 receptor (IGF-1R). Teprotumumab binds to the ligand-binding domain of the extracellular alpha subunit of IGF-1R. It inhibits the actions of TSH and IGF-1 in fibroblasts. Teprotumumab reduces the expression of IL-6 and IL-8, which are dependent on TSH, as well as phosphorylation of Akt. It can be used for research related to thyroid-associated eye disease.

     Teprotumumab Chemical Structure
  37. GC63215 Terevalefim

    ANG-3777

     Terevalefim (ANG-3777), an hepatocyte growth factor (HGF) mimetic, selectively activates the c-Met receptor. Terevalefim Chemical Structure
  38. GC31752 Tesevatinib (XL-647)

    EXEL-7647, Tesevatinib

     Tesevatinib (XL-647) (XL-647; EXEL-7647; KD-019) is an orally available, multi-target tyrosine kinase inhibitor; inhibits EGFR, ErbB2, KDR, Flt4 and EphB4 kinase with IC50s of 0.3, 16, 1.5, 8.7, and 1.4 nM. Tesevatinib (XL-647) Chemical Structure
  39. GC37771 TG 100572 TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively. TG 100572 Chemical Structure
  40. GC37772 TG 100572 Hydrochloride TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively. TG 100572 Hydrochloride Chemical Structure
  41. GC11622 TG 100801 TG 100801 Chemical Structure
  42. GC37773 TG 100801 Hydrochloride TG 100801 Hydrochloride is a prodrug that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively. TG 100801 Hydrochloride Chemical Structure
  43. GC10035 TG101209 An inhibitor of JAK2, FLT3, RET, and JAK3 TG101209 Chemical Structure
  44. GC38081 Theliatinib Theliatinib (Xiliertinib) is a potent, ATP-competitive, orally active and highly selective EGFR inhibitor with a Ki of 0.05 nM and an IC50 of 3 nM. Theliatinib has an IC50 of 22 nM for EGFR T790M/L858R mutant. Theliatinib shows >50-fold selectivity for EGFR than other kinases. Anti-tumor activity. Theliatinib Chemical Structure
  45. GC60365 TIE-2/VEGFR-2 kinase-IN-1 TIE-2/VEGFR-2 kinase-IN-1 is used for the synthesis of TIE-2 and/or VEGFR-2 inhibitors, extracted from patent WO2003022852, example 14. TIE-2/VEGFR-2 kinase-IN-1 Chemical Structure
  46. GC14898 Tie2 kinase inhibitor

    Tunica Interna Endothelial Cell Kinase 2 Inhibitor

     Tie2 kinase inhibitor (compound 5) is a potent, selective Tie2 kinase inhibitor with an IC50 of 250 nM. Tie2 kinase inhibitor has anti-cancer activity. Tie2 kinase inhibitor Chemical Structure
  47. GC68342 Tilvestamab

    BGB149

     Tilvestamab Chemical Structure
  48. GC49062 Tiopronin-d3

    (±)-Tiopronin-d3

     An internal standard for the quantification of tiopronin Tiopronin-d3 Chemical Structure
  49. GC34109 Tirbanibulin Mesylate (KX2-391 (Mesylate))

    KX2-391 Mesylate; KX01 Mesylate

     Tirbanibulin Mesylate (KX2-391 (Mesylate)) (KX2-391 Mesylate) is an inhibitor of Src that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Tirbanibulin Mesylate (KX2-391 (Mesylate)) Chemical Structure
  50. GC14256 Tivantinib (ARQ 197)

    ARQ-197;ARQ197

     Tivantinib (ARQ 197) is a highly selective c-Met tyrosine kinase inhibitor with a Ki of 355 nM. Tivantinib (ARQ 197) Chemical Structure
  51. GC12036 Tivozanib (AV-951) Tivozanib (AV-951; KRN951) is a potent and selective and orally active VEGFR tyrosine kinase inhibitor with IC50是of 0.21, 0.16, 0.24 nM for VEGFR-1, VEGFR-2, VEGFR-3, respectively. Tivozanib inhibits angiogenesis and vascular permeability in tumor tissues and shows antitumor activity. Tivozanib has the potential for the research of metastatic renal cell carcinoma (RCC) . Tivozanib (AV-951) Chemical Structure
  52. GC15280 Tivozanib (hydrate)

    AV-951,KRN 951

     VEGFR inhibitor, orally available Tivozanib (hydrate) Chemical Structure
  53. GC64996 Tivozanib hydrochloride hydrate Tivozanib hydrochloride hydrate Chemical Structure
  54. GC50562 TL 13-110 Negative control for TL 13-112 TL 13-110 Chemical Structure
  55. GC50563 TL 13-22 Negative control for TL 13-12 TL 13-22 Chemical Structure
  56. GC38864 TL02-59 TL02-59 is an orally active, selective Src-family kinase Fgr inhibitor with an IC50 of 0.03 nM. TL02-59 inhibits Lyn and Hck with IC50s of 0.1 nM and 160 nM, respectively. TL02-59 potently suppresses acute myelogenous leukemia (AML) cell growth. TL02-59 Chemical Structure
  57. GC67878 TL4830031 TL4830031 Chemical Structure
  58. GC11496 TLQP 21 TLQP 21 Chemical Structure
  59. GC31163 TMP778

    TMP778 is a potent and selevtive RORγt inverse agonist, with an IC50 of 7 nM in FRET assay.

     TMP778 Chemical Structure
  60. GC62520 TMP780 TMP780 is an inverse agonist of RORγt with an IC50 of 13 nM. TMP780 Chemical Structure
  61. GC39299 TMP920 TMP920 is a highly potent and selective RORγt antagonist. TMP920 Chemical Structure
  62. GC10719 Toceranib

    PHA 291639, SU11654

     A multi-targeted receptor tyrosine kinase inhibitor Toceranib Chemical Structure
  63. GC37808 Toceranib phosphate Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib phosphate (SU11654 phosphate) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors . Toceranib phosphate Chemical Structure
  64. GC66385 Tovetumab

    MEDI-575

     Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC). Tovetumab Chemical Structure
  65. GC14218 TP-0903

    TP-0903

     TP-0903 (TP-0903) is a potent and selective Axl receptor tyrosine kinase inhibitor with an IC50 value of 27 nM. TP-0903 Chemical Structure
  66. GC26001 TPX-0046 TPX-0046 Chemical Structure
  67. GC62260 TPX-0131

    TPX-0131

     TPX-0131 is a potent, selective, CNS-penetrant and orally active inhibitor of wild-type ALK (IC50 of 1.4 nM) and ALK-resistant mutation, e.g. G1202R (IC50 of 0.3 nM), L1196M (IC50 of 0.3 nM). TPX-0131 has strong antitumor activities. TPX-0131 Chemical Structure
  68. GC32458 Trapidil (AR-12008)

    Triazolopyrimidine

     Trapidil (AR-12008) is a vasodilator, is an antiplatelet drug with specific platelet-derived growth factor. Trapidil (AR-12008) Chemical Structure
  69. GC34215 Trastuzumab (Anti-Human HER2, Humanized Antibody) Trastuzumab (Anti-Human HER2, Humanized Antibody) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (Anti-Human HER2, Humanized Antibody) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research. Trastuzumab (Anti-Human HER2, Humanized Antibody) Chemical Structure
  70. GC61473 Trastuzumab deruxtecan

    DS-8201 (solution); DS-8201a (solution)

     Trastuzumab deruxtecan (DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, and a topoisomerase I inhibitor. Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer. Trastuzumab deruxtecan Chemical Structure
  71. GC61490 Trastuzumab emtansine Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer. Trastuzumab emtansine Chemical Structure
  72. GC60372 TrkA-IN-1 TrkA-IN-1 is a potent and selective Tropomyosin-related kinase A (TrkA) inhibitor with an IC50 of 99 nM in a cell-based assay. TrkA-IN-1 Chemical Structure
  73. GC70064 TrkA-IN-3

    TrkA-IN-3 is an effective and sub-selective TrkA allosteric inhibitor with an IC50 value of 22.4 nM. TrkA-IN-3 exhibits a selectivity for TrkA over TrkB and TrkC by 8000-fold. It can be used in the study of pain.

     TrkA-IN-3 Chemical Structure
  74. GC70065 TrkA-IN-4

    TrkA-IN-4 is an effective and orally active TrkA allosteric inhibitor, which is a precursor of TrkA-IN-3. TrkA-IN-4 exhibits effective anti-injury activity.

     TrkA-IN-4 Chemical Structure
  75. GC16732 TSU-68 (SU6668,Orantinib)

    NSC 702827, Orantinib, TSU68

     TSU-68 (SU6668,Orantinib) (SU6668; TSU-68) is a multi-targeted receptor tyrosine kinase inhibitor with Kis of 2.1 μM, 8 nM and 1.2 μM for Flt-1, PDGFRβ and FGFR1, respectively. TSU-68 (SU6668,Orantinib) Chemical Structure
  76. GC32726 Tucatinib (Irbinitinib)

    ARRY-380, ONT-380

     Tucatinib (Irbinitinib) (Irbinitinib) is a potent, orally active and selective HER2 inhibitor with an IC50 of 8 nM. Tucatinib (Irbinitinib) Chemical Structure
  77. GC62159 Tucatinib hemiethanolate Tucatinib (Irbinitinib) hemiethanolate is a potent, orally active and selective HER2 inhibitor with an IC50 of 8 nM. Tucatinib hemiethanolate Chemical Structure
  78. GC70077 Tunlametinib

    Tunlametinib is an anti-tumor compound and a tyrosine kinase inhibitor.

     Tunlametinib Chemical Structure
  79. GC69233 Tuspetinib

    HM43239

    Tuspetinib (HM43239) is a selective FLT3 inhibitor with oral activity, with IC50 values of 1.1 nM (wild-type FLT3), 1.8 nM (FLT3 ITD mutation), and 1.0 nM (FLT3 D835Y mutation). As a reversible type I inhibitor, Tuspetinib directly inhibits the kinase activity of FLT3 and regulates p-STAT5, p-ERK SYK, JAK1/2, and TAK1. Tuspetinib inhibits the proliferation of leukemia cells and induces apoptosis.

     Tuspetinib Chemical Structure
  80. GC34847 TX1-85-1 An ErbB3 inhibitor TX1-85-1 Chemical Structure
  81. GC37849 Tyrosine kinase inhibitor Tyrosine kinase inhibitor is a potent tyrosine kinase inhibitor. Tyrosine kinase inhibitor Chemical Structure
  82. GC34026 Tyrosine kinase-IN-1 Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor with IC50s of 4, 20, 4, 2 nM for KDR, Flt-1, FGFR1 and PDGFRα, respectively. Tyrosine kinase-IN-1 Chemical Structure
  83. GC10758 Tyrphostin 9

    GCP 5126, Malonoben, NSC 242557, RG50872, SF 6847, Tyrphostin 9, Tyrphostin AG17

     Tyrphostin 9, a PDGFR inhibitor, is a potent inducer of mitochondrial fission. Tyrphostin 9 Chemical Structure
  84. GC13045 Tyrphostin AG 1296

    Tyrphostin AG1296

     PDGFR inhibitor,selective and ATP-competitive Tyrphostin AG 1296 Chemical Structure
  85. GC19364 Tyrphostin AG 528

    Tyrphostin AG-528

     Tyrphostin AG 528 is an inhibitor of EGFR and ErbB2 with IC50s of 4.9 and 2.1 uM, respectively. Tyrphostin AG 528 Chemical Structure
  86. GC15271 Tyrphostin AG 879

    Tyrphostin AG879

     HER2 inhibitor Tyrphostin AG 879 Chemical Structure
  87. GC39314 Tyrphostin AG1433

    SU1433; AG1433

     Tyrphostin AG1433 (SU1433) is a tyrosine kinases inhibitor. AG1433 is also a selective PDGFRβ and VEGFR-2 (Flk-1/KDR) inhibitor with IC50s of 5.0 μM and 9.3 μM, respectively. Tyrphostin AG1433 prevents blood vessel formation. Tyrphostin AG1433 Chemical Structure
  88. GC38125 Tyrphostin AG30 Tyrphostin AG30 (AG30) is a potent and selective EGFR tyrosine kinase inhibitor. Tyrphostin AG30 (AG30) selectively inhibits self renewal induction by c-ErbB, and is able to inhibit activation of STAT5 by c-ErbB in primary erythroblasts. Tyrphostin AG30 Chemical Structure
  89. GC15038 Tyrphostin B44, (+) enantiomer Tyrphostin B44, (+) enantiomer (Tyrphostin AG 835) (Compound B50) is an EGRF inhibitor with antitumor activities. Tyrphostin B44, (+) enantiomer Chemical Structure
  90. GC12977 Tyrphostin B44, (-) enantiomer EGFR-kinase inhibitor Tyrphostin B44, (-) enantiomer Chemical Structure
  91. GC68463 ULK1-IN-2 ULK1-IN-2 Chemical Structure
  92. GC19366 UM-164

    DAS-DFGO-II

     UM-164 is a highly potent inhibitor of c-Src with a Kd of 2.7 nM. UM-164 Chemical Structure
  93. GC15556 UNC2025 orally bioavailable dual MER/FLT3 inhibitor UNC2025 Chemical Structure
  94. GC37857 UNC2025 hydrochloride UNC2025 hydrochloride is a potent, ATP-competitive, and highly orally active Mer/Flt3 inhibitor with IC50 values of 0.74 nM and 0.8 nM, respectively. UNC2025 hydrochloride is >45-fold selectivity for MERTK relative to Axl (IC50= 122 nM; Ki?= 13.3 nM). UNC2025 hydrochloride exhibits an excellent PK properties, and can be used for the investigation of acute leukemia. UNC2025 hydrochloride Chemical Structure
  95. GC17793 UNC2250 Mer inhibitor,potent and selective UNC2250 Chemical Structure
  96. GC37858 UNC2541 UNC2541 is a potent and Mer tyrosine kinase (MerTK)-specific inhibitor, binds in the MerTK ATP pocket, with an IC50 of 4.4 nM, more selective over Axl, Tyro3 and Flt3. UNC2541 Chemical Structure
  97. GC13500 UNC2881 Mer tyrosine kinase inhibitor UNC2881 Chemical Structure
  98. GC62516 UNC5293 UNC5293 is a MERTK-selective and potent inhibitor (Ki=190 pM). UNC5293 inhibits MERTK (IC50=0.9 nM) and is more selective over Axl, Tyro3 and Flt3. UNC5293 exhibits excellent mouse PK properties and is used for bone marrow leukemia research. UNC5293 Chemical Structure
  99. GC64856 UniPR129 UniPR129 is a potent Eph/ephrin antagonist. UniPR129 has the potential for the research of cancer disease. UniPR129 Chemical Structure
  100. GC70097 Urolithin D

    Urolithin D is a competitive and reversible antagonist of the EphA receptor. Urolithin D exhibits intra-class selectivity.

     Urolithin D Chemical Structure
  101. GC70110 Vamotinib

    PF-114

    Vamotinib (PF-114) is an effective, selective and orally active tyrosine kinase inhibitor. Vamotinib inhibits the self-phosphorylation of BCR/ABL and BCR/ABL-T315I. Vamotinib induces apoptosis. Vamotinib exhibits anti-proliferative and anti-tumor activity. Vamotinib has potential in the study of resistant Philadelphia chromosome-positive (Ph+) leukemia.

     Vamotinib Chemical Structure

Items 1001 to 1100 of 1157 total

per page
  2. 8
  3. 9
  4. 10
  5. 11
  6. 12

Set Descending Direction